Citalopram to treat depression in pediatric oncology

Margaret DeJong, Eric Fombonne

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective re-uptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.

Original languageEnglish (US)
Pages (from-to)371-377
Number of pages7
JournalJournal of Child and Adolescent Psychopharmacology
Issue number3
StatePublished - Jun 2007
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Citalopram to treat depression in pediatric oncology'. Together they form a unique fingerprint.

Cite this